Hua Medicine (Shanghai) Ltd. (HKG:2552)
Hong Kong
· Delayed Price · Currency is HKD 3.340
+0.240 (7.74%)
Mar 10, 2026, 4:08 PM HKT
Hua Medicine (Shanghai) Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Operating Revenue | 370.66 | 255.89 | 76.61 | 17.6 | - | - | Upgrade
|
| Other Revenue | - | - | - | - | - | 8.66 | Upgrade
|
| Revenue | 370.66 | 255.89 | 76.61 | 17.6 | - | 8.66 | Upgrade
|
| Revenue Growth (YoY) | 240.24% | 234.02% | 335.31% | - | - | -61.07% | Upgrade
|
| Cost of Revenue | 175.88 | 131.17 | 39.24 | 9.91 | - | - | Upgrade
|
| Gross Profit | 194.78 | 124.72 | 37.37 | 7.69 | - | 8.66 | Upgrade
|
| Selling, General & Admin | 265 | 269.94 | 203.9 | 145.28 | 134.84 | 140.08 | Upgrade
|
| Research & Development | 161.14 | 215.09 | 171.54 | 129.53 | 186.84 | 220.96 | Upgrade
|
| Operating Expenses | 426.13 | 485.03 | 375.44 | 274.81 | 321.67 | 361.05 | Upgrade
|
| Operating Income | -231.35 | -360.31 | -338.07 | -267.12 | -321.67 | -352.38 | Upgrade
|
| Interest Expense | -8.7 | -8.61 | -7.91 | -3.67 | -3.95 | -4.4 | Upgrade
|
| Interest & Investment Income | 15.33 | 13.44 | 16.51 | 4.24 | 5.04 | 4.37 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.15 | 2.02 | 4.14 | 26.03 | -10.37 | -41.83 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,301 | 103.32 | 114.09 | 37.27 | 4.88 | -1.72 | Upgrade
|
| EBT Excluding Unusual Items | 1,076 | -250.14 | -211.23 | -203.25 | -326.08 | -395.96 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -0.26 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.35 | 2.83 | Upgrade
|
| Pretax Income | 1,076 | -250.14 | -211.23 | -203.51 | -325.73 | -393.13 | Upgrade
|
| Earnings From Continuing Operations | 1,076 | -250.14 | -211.23 | -203.51 | -325.73 | -393.13 | Upgrade
|
| Net Income | 1,076 | -250.14 | -211.23 | -203.51 | -325.73 | -393.13 | Upgrade
|
| Net Income to Common | 1,076 | -250.14 | -211.23 | -203.51 | -325.73 | -393.13 | Upgrade
|
| Shares Outstanding (Basic) | 984 | 981 | 977 | 967 | 957 | 951 | Upgrade
|
| Shares Outstanding (Diluted) | 987 | 981 | 977 | 967 | 957 | 951 | Upgrade
|
| Shares Change (YoY) | 0.69% | 0.44% | 1.07% | 0.97% | 0.73% | 0.90% | Upgrade
|
| EPS (Basic) | 1.09 | -0.25 | -0.22 | -0.21 | -0.34 | -0.41 | Upgrade
|
| EPS (Diluted) | 1.09 | -0.25 | -0.22 | -0.21 | -0.34 | -0.41 | Upgrade
|
| Free Cash Flow | -283.53 | -420.8 | 879.63 | -234.67 | -293.18 | -45.27 | Upgrade
|
| Free Cash Flow Per Share | -0.29 | -0.43 | 0.90 | -0.24 | -0.31 | -0.05 | Upgrade
|
| Gross Margin | 52.55% | 48.74% | 48.79% | 43.69% | - | 100.00% | Upgrade
|
| Operating Margin | -62.42% | -140.80% | -441.28% | -1517.80% | - | -4067.20% | Upgrade
|
| Profit Margin | 290.30% | -97.75% | -275.73% | -1156.36% | - | -4537.56% | Upgrade
|
| Free Cash Flow Margin | -76.49% | -164.44% | 1148.19% | -1333.44% | - | -522.55% | Upgrade
|
| EBITDA | -217.29 | -345.99 | -322.24 | -254.82 | -309.69 | -347.43 | Upgrade
|
| EBITDA Margin | -58.62% | -135.21% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 14.06 | 14.32 | 15.83 | 12.3 | 11.98 | 4.95 | Upgrade
|
| EBIT | -231.35 | -360.31 | -338.07 | -267.12 | -321.67 | -352.38 | Upgrade
|
| EBIT Margin | -62.42% | -140.80% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.